
DIGEST

The digest printed below was prepared by House Legislative Services. It constitutes no part of the legislative instrument. The keyword, one-liner, abstract, and digest do not constitute part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]

HB 436 Reengrossed

2017 Regular Session

Talbot

Abstract: Requires the disclosure of prescription drug price information.

Proposed law requires each drug manufacturer or pharmaceutical marketer who engages in any form of prescription drug marketing to a prescriber, his designee, or any member of his staff in La. to provide to the La. Board of Pharmacy no later than Jan. 1st, Apr. 1st, July 1st, and Oct. 1st of each calendar year the current wholesale acquisition cost information for the U.S. Food and Drug Administration approved drugs marketed in the state by that manufacturer.

Proposed law defines "prescription drug" and "prescription drug marketing".

(Adds R.S. 40:2255.1 and 2255.11)

Summary of Amendments Adopted by House

The Committee Amendments Proposed by House Committee on Health and Welfare to the original bill:

1. Require an annual report of certain prescription drug claims data by health insurance issuers and pharmacy benefit managers.
2. Delete provisions allowing recommendations for additional drugs to be included on the critical prescription drug list.
3. Delete the requirement that drug manufacturers disclose pricing information to the committee.
4. Delete provisions authorizing enforcement under the Unfair Trade Practices and Consumer Protection Law.
5. Make technical changes.

The House Floor Amendments to the engrossed bill:

1. Delete proposed legislative findings.
2. Delete proposed law definition of "average wholesale price", "committee", "department",

and "manufacturer".

3. Delete proposed law establishing the Prescription Drug Review Committee, including provisions relative to the critical prescription drug list, manufacturer reporting, rulemaking authority, and the annual report on prescription drug prices submitted to the legislature.
4. Delete proposed law requiring any person engaging in prescription drug marketing directly to a healthcare provider to provide pricing information. Instead, adds a provision that requires each drug manufacturer or pharmaceutical marketer engaging in prescription drug marketing to a prescriber to provide the wholesale acquisition cost of approved drugs marketed in the state to the La. Board of Pharmacy.
5. Delete proposed law establishing a public records exception.
6. Make technical changes.